Form D · Biotechnology

AVILA THERAPEUTICS INC

Waltham, MA · CIK 0001433874

Offering snapshot reported Jul 6, 2010 · SEC filing

Reported sold: $22.5M
Investors reported: 9
Minimum accepted: $0
First sale: Jul 16, 2009

Fundraising history

Reported sold

Dates are filing dates, not cash receipt dates. Decreases are reported revisions, not evidence of withdrawals. Separate offering histories are not added together.

What changed?

Latest filing versus its linked predecessor, where available.

Reported sold$17,500,000 → $22,500,000
Minimum accepted$9,531 → $0

Filing history

Scroll to see all columns →

Filed	Filing type	Reported sold	Change vs linked filing	Investors	Source
Jul 6, 2010	Amendment	$22,500,000	$5,000,000vs Jul 31, 2009	9	SEC filing
Jul 31, 2009	Initial	$17,500,000	No comparison	9	SEC filing
May 14, 2009	Initial	$5,000,000	No comparison	Not reported	SEC filing
Apr 25, 2008	Paper	Not reported	No comparison	Not reported	SEC filing

Offering details

Securities: Equity
Exemptions: 06
Duration over one year: No
Business combination: No

Sales commissions: $0
Finders' fees: $0
Form D file number: 021-117636

Source: Form D, filed Jul 6, 2010. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
Name	Reported role
Michael F. Bigham	Director, Executive
Bruce Booth	Director
Katrine Bosley	Director, Executive
Roy R. Lobb	Director, Executive
Daniel Lynch	Director, Executive
Amir Nashat	Director
Raj Parekh	Director
Vicki Sato	Director
Henry Skinner	Director

Issuer details

Industry: Biotechnology (See others in industry)

Address:

100 Beaver Street
Waltham, MA, 02453